Abstract
Introduction
Extracorporeal life support (ECLS) is a life-saving technology employing a modified form of cardiopulmonary bypass. ECLS therapy is used in severe cardiac or cardiopulmonary failure due to post-cardiotomy low cardiac output syndrome (LCOS), cardiopulmonary resuscitation, acute myocardial infarction with LCOS, myocarditis or decompensated chronic heart failure. [1] [2] [3] [4] Today, this rescue therapy offers as a bridge to recovery or as a bridge to decision the opportunity for further treatment and evaluation of patients suffering from severe cardiogenic shock. 5 Nevertheless, the outcome
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of ECLS patients is remarkably affected by end-organ function. 4, 6, 7 Despite notable advances in the quality of devices and in intensive care management of these patients, ECLS therapy is still associated with a high rate of mortality and complications. 5 In addition, it requires considerable human and financial resources. For these reasons, identifying early prognostic indicators and developing a score with regard to the outcome of this special patient population is of high interest. 8, 9 The often-unexpected necessity of ECLS implies that information about end-organ function is, at this time, not available or, e.g. in post-cardiotomy LCOS, not helpful. With regard to kidney injury, AKIN (acute kidney injury network) classification may correctly predict ECLS outcome. 10 However, this classification is based on changes in values which are frequently not available in the pre-operative situation or are probably worthless in post-cardiotomy LCOS. Widely used intensive care scores for cardiac patients like, CASUS 11 and SOFA, 12 are initially not applicable due to the rapid decision process. 13 Twelve hours after ECLS initiation, all relevant parameters and scores are available and applicable. In our view, this is a good point in time to assess the efficacy of ECLS therapy and signs of profound secondary organ injuries resulting from late therapy onset. Therefore, we decided to evaluate a setting of clinical data in ECLS patients, including established laboratory parameters, need for catecholamine, AKIN classification and scores like CASUS and SOFA twelve hours after ECLS implantation. The aim of this retrospective analysis was to determine prognostic outcome predictors at a time when ECLS patients should be stabilized and on their road to recovery.
Patients and Methods

Study Patients
In the present study, we retrospectively assessed 90 adult patients (65 males, 25 females) with established veno-arterial ECLS therapy between January 2011 and December 2012. The study was approved by the local Ethics Committee of the Medical Faculty of MartinLuther-University, Halle-Wittenberg (ethical approval number 2015-127, November 18 th , 2015) and confirmed that no patient consent was required because of the retrospective, descriptive and anonymous design. All data were acquired 12 h after ECLS implantation. All devices were implanted at the Department of Cardiac Surgery, University Hospital Halle (Saale). Sixty-eight high risk patients (3.73% of 1824 patients with cardiopulmonary bypass during the study period) with intra-operative post-cardiotomy LCOS were placed on ECLS when weaning from cardiopulmonary bypass was not successful, even with maximized inotropic support. The other patients required ECLS due to circulatory failure caused by an underlying cardiac disease. Leading criteria for ECLS decision included increasing need for inotropic support and signs of end-organ failure despite maximized intensive care therapy. Once established, management of the ECLS aimed at maintaining stable organ perfusion and oxygenation. Full ECLS flow was typically facilitated for 24 to 72 hours before the weaning process was started. All patients with peripheral ECLS had a distal leg perfusion cannula. We tried to maintain the ECLS blood flow greater than the cardiac index of 2.4 L/min/m 2 (ECLS flow rate ≥3.5 L/min) and to reach a mean arterial pressure of ≥70 mm Hg. Therapeutic goals of ECLS therapy were to decrease inotropic and vasopressor support and invasiveness of mechanical ventilation to assist cardiopulmonary recovery. Transthoracic or transoesophageal echocardiography was performed before starting ECLS weaning. Weaning was performed, with slow reduction of ECLS flow (1-1.5 L/min/day), every 12 to 24 hours, only under stable hemodynamic and metabolic conditions. The ECLS flow was never reduced to less than 1.5 L/min until explantation to avoid any intrasystemic clotting.
Data Collection
For all patients with ECLS, clinical variables were prospectively entered in our institutional database. Forty-five variables were evaluated by simple and multivariable regression analysis, with respect to inhospital mortality. All clinical laboratory parameters were assessed by the central department of Laboratory Medicine of the University Hospital.
Score Calculation
The additive CASUS, including ten variables and six organ systems (respiratory, renal, liver, cardiovascular, coagulation and central nervous), was calculated according to Hekmat et al. 11, 14 with the online calculator (www. cardiac-icu.org). The SOFA score is made of 6 variables, each representing an organ system 12, 15 . In both scoring systems, point values are assigned from 0 (normal) to 4 (high degree of dysfunction/failure).
Statistical Analyses
Categorical variables were expressed as frequencies and percentages. Metric variables were expressed as mean ± standard deviation (SD). Statistical analysis was done using the MedCalc ® 13.02 program. To predict risk factors for in-hospital mortality, simple and multivariable logistic regression analyses were done to estimate the odds ratio (OR) with their 95% confidence intervals (CI). Goodness-of-fit was assessed using the HosmerLemeshow test to compare the number of observed and predicted deaths in risk groups for the entire range of death probabilities. Discrimination was assessed using the area under the receiver-operating characteristic curve (AUROC) at the time point MP1 (12 h after ECLS initiation). AUROC analysis was also utilized to calculate cut-off values, sensitivity, specificity and overall correctness. Finally, cut-off points were identified by obtaining the best Youden index. Cumulative survival curves as a function of time were generated utilizing the Kaplan-Meier approach. P-values of less than 0.05 were considered significant.
Results
In the present study, we assessed 90 patients (mean age: 62.1 ± 13.8 years, range 18-79 years) with established veno-arterial ECLS. Twenty-five (27.8%) of the 90 patients were females and they were older (64.9 ± 15.6 years) than the males (60.9 ± 13.1 years). The pre-operative left ventricular ejection fraction was reduced to 30 ± 16% in the total patient population and was 27 ± 14.3% in the patients who died. The most common indication for ECLS implantation was low cardiac output syndrome (LCOS) after major cardiac surgery which occurred in 75.6% (n=68) of the patients. The preoperative EuroScore II values for the surgical patients were 48.6 ± 22.1% (survivors 40.4 ± 20.7%; nonsurvivors 58.5 ± 19.7%; OR=1.04; 95% CI, 1.02-1.07; p=0.004). Ten patients (11.1%) needed ECLS support after in-hospital cardiopulmonary resuscitation due to acute myocardial infarction (n=7) and fulminant pulmonary embolism with right ventricular failure (n=3). Other reasons for ECLS implantation were acute myocardial infarction (n=6), septic shock with cardiomyopathy (n=4), decompensated heart failure (n=1) and myocarditis (n=1). Mortality for ECLS patients with surgical (n=68; non-survivors n=31) and medical (n=22; non-survivors n=11) driven indication did not show differences (OR=1.19; 95% CI, 0.46-3.12; p=0.72). Further demographic and clinical data of the study individuals in total and the ECLS therapy survivors are shown in Table 1 . Operation types of the 68 patients receiving ECLS for post-operative LCOS are provided in Table 1 ; only aortic surgery for dissection was associated with a higher mortality risk. Twelve hours after ECLS initiation, we assessed established laboratory parameters as well as patient-related data and ICU scores. Details of the relevant parameters, CASUS and SOFA are shown in Table 2 . Mean duration of ECLS was 7.9 ± 2.5 days (range <1 -22 days). Major complications that arose during ECLS therapy were bleeding in 50% (n=45) of all patients and 46.7% (n=21) of the survivors, however, there was no significant influence on the overall mortality (OR=0.58; 95% CI, 0.25 − 1.35; p=0.21). Twenty-five patients with ECLS after cardiac surgery (27.8% of the total cohort; 20.8% (n=10) of the survivors) required reoperation due to mediastinal bleeding (OR=2.1; 95% CI, 0.82-5.4; p=0.12). Among 10 (11.1%) patients who had complications associated with cannulation-related distal limb ischemia, two developed a compartment syndrome. New-onset neurologic events occurred in five (5.5%) patients, including intracerebral haemorrhage in two, cerebral infarction in one, and cerebral hypoxia in two patients. Successful ECLS weaning was possible in 67.8% (n=61) of the patients whereas 53.3% (n=48) could be successfully discharged from the hospital. Four patients were switched to a left ventricular assist device. The main reasons for in-hospital death of ECLS patients were multi-organ-failure in 27.8% (n=25), followed by global cardiac failure in 10% (n=9) and severe sepsis with multiorgan-dysfunction syndrome in 8.9% (n=8). The mean duration of hospital stay for survivors after initiation of ECLS was 33.8 ± 16.5 days. Eight of the 48 survivors were discharged to their home, 24 were referred to rehabilitation clinics, 14 were transferred to other hospitals and two patients were discharged to nursing homes.
Independent Predictors of Mortality
Multivariable logistic analysis revealed high serum lactate level, urine output and CASUS 12 hours after ECLS initiation as independent factors associated with in-hospital mortality (Table 3A and B). CASUS and SOFA score were assessed for goodness-of-fit with the Hosmer-Lemeshow test (p=0.153). The discriminative abilities in terms of in-hospital mortality prediction for ECLS patients are provided in Table 4A . AUROC analysis confirms that the discriminative power of CASUS exceeds that of the SOFA score. To assess the predictive value of each parameter for in-hospital mortality, we determined sensitivity, specificity and overall correctness of prediction. CASUS, urine output and AKIN classification had the best Youden index and highest overall prediction correctness (Table 4B ). Figure 1A shows the cumulative rates of survival for the study group dichotomized by 19 CASUS points or less and 20 CASUS points or more (p=0.0004). Cumulative survival rates also differed considerably (p=0.02) between patients with normal kidney function or AKIN I and AKIN stage II and III ( Figure 1B ).
Discussion
Extracorporeal circulatory life support is widely accepted as a temporary mechanical support for rescue therapy in emergency and unexpected cardiogenic shock today. It is easily and rapidly applicable, thereby, opening the opportunity of immediate biventricular and respiratory support. In the present study, the rate of successful weaning from ECLS was 67.8% and hospital survival was 53.3%. These results are in line with data reported by the Extracorporeal Life Support Organization (ELSO) registry. 5 Our data and results from other groups suggest an improvement in early survival of ECLS patients over the last years due to technically advanced devices and better patient management. 6, [16] [17] [18] Our goal should be the early initiation of ECLS ahead of the onset of profound cardiopulmonary failure and secondary organ injuries. 17 In low-flow states like LCOS or cardio-respiratory arrest, hyperlactatemia is related to inadequate cellular oxygen utilization and the development of an anaerobic metabolism. 19 Hyperlactatemia under these conditions may also be driven by the use of greater amounts of inotrope agents. However, even if changes in lactate are slower than changes in systemic arterial pressure or cardiac output, the blood lactate level should decrease with an effective therapy within 12 hours. So far, no clear consensus exists on the cut-off value determining severe hyperlactatemia. However, there is evidence that, at lactate levels >10 mmol/L, liver and kidney become saturated for lactic acid uptake. 20 Park et al. 21 and a number of other authors 17, 18, 22 reported a strong correlation of the outcome for ECLS patients with the severity of pre-ECLS cardiogenic shock, reflected by increased lactate levels. Rigamonti et al. 18 as well as Li et al. 17 described that lactate levels 6 to 24 hours after ECLS initiation are solidly linked to the mortality of the supported patients. In our patients, we found that lactate levels of ≥6.5 mmol/L 12 hours after ECLS initiation were correlated with an adverse outcome. ECLS therapy results are also strongly affected by bleeding complications, limb ischemia and thromboembolic events. 23 Patients requiring ECLS therapy frequently have multi-organ-failure and suffer from disorders of hemostasis due to an imbalance of their procoagulant and anticoagulant pathways. 24 Additionally, ECLS support causes platelet activation, inflammation and consumption of clotting factors. Unfractionated heparin (UFH) remains the most widely utilized anticoagulant during ECLS therapy. APTT measurement has been used as the gold standard for monitoring UFH. 25 In 2014, the ELSO published the first expert anticoagulation guideline; 26 they recommended that every ECLS program develops an individualized approach to monitor UFH. 27 In our institution, heparin dose is titrated to maintain aPTT levels of 50-60 seconds, measured every six hours, according to suggestions of Maul et al. 28 Decreased urine output and the development of acute kidney injury (AKI) after major cardiac surgery are well recognized complications that occur in up to 40% of the patients. 29 Chang et al., 30 reported in patients successfully weaned from ECMO support, a strong correlation of decreased daily urine output and AKI with an adverse outcome. We noticed that urine output below 68 mL/h and AKIN stage II -III, 12 hours after ECLS initiation were associated with increased in-hospital mortality and lower short-term survival rates. CASUS and SOFA have been recommended as the most reliable scores for benchmarking and risk stratification in cardiac surgery patients. 31 In 2005, CASUS was specifically developed for cardiac surgery patients. 11 therefore we hypothesized that CASUS would perform better in the ECLS patient population. Indeed, in our study, CASUS predicted in-hospital mortality and short-term prognosis far better than SOFA. In our view, 12 hours after ECLS initiation is a good point in time to assess efficacy of ECLS therapy and prognosis of patients. A CASUS of ≥20 points at this stage predicts a 100-day survival probability of only 20%. The consequence of this assessment will be a discussion of each case in our ECLS team visit and a clear conversation with patient relatives about the unfavorable prognosis.
Study Limitations
Our study is subject to the limitations inherent in retrospective observational studies from a single center. Additionally, because of the small sample population and numbers of complications, the use of lactate, urine output, AKIN classification and CASUS as early predictors for in-hospital mortality and prognosis of ECLS patients require further evaluation. This will be implemented within our subsequent work.
Conclusions
In conclusion, this study observed an in-hospital mortality rate of 53.3% in critically ill patients weaned from ECLS support. To our knowledge, this is the first study to confirm that, in addition to lactate, urine output and AKIN classification, the CASUS, assessed 12 hours after ECLS initiation, is highly associated with the patient's outcome. A CASUS of ≥20 points was correlated with increased in-hospital mortality. Further, our data demonstrate a good power for CASUS to predict survival of ECLS patients. Therefore, we recommend using the CASUS to assess short-term prognosis in this subset of patients.
